Ephedra Supplements Contain Low PPA Levels, Cantox Report Indicates
This article was originally published in The Tan Sheet
Executive Summary
FDA's recent advisory urging consumers not to use phenylpropanolamine-containing OTCs should not dissuade people from taking ephedrine alkaloid-containing dietary supplements to lose weight and enhance workouts, a Cantox Health Sciences International report on the herbal suggests.
You may also be interested in...
Ephedra/AER Causality Link Not Possible - Cantox/CRN
Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.
Retailer In-Store Signs Explain PPA Product Removal To Customers
Drugstore chains including Walgreens, Rite Aid, Kroger's and CVS are developing signs to explain to consumers why phenylpropanolamine-containing products have been voluntarily removed from store shelves.
Ephedra/Caffeine Combos Sought In Industry Citizen Petition
FDA adoption of industry's four-year-old voluntary guidelines for labeling and marketing of ephedra-containing dietary supplements, as well as agency clearance for continued sales of ephedra/caffeine combination products, is requested by a coalition of supplement trade groups in a recent citizen petition.